Entrada Therapeutics (TRDA) Asset Utilization Ratio (2023 - 2026)

Entrada Therapeutics' Asset Utilization Ratio history runs 4 years deep, the most recent figure standing at 0.02 for Q1 2026.

• In Q1 2026, Asset Utilization Ratio fell 95.27% year-over-year to 0.02; the TTM figure through Mar 2026 stood at 0.02 (down 95.27% YoY), while the FY2025 annual figure was 0.06, down 86.71% from the prior year.
• Asset Utilization Ratio for Q1 2026 stood at 0.02, down from 0.06 in the prior quarter.
• The five-year high for Asset Utilization Ratio was 0.44 in Q2 2024, with the low at 0.02 in Q1 2026.
• The 4-year median for Asset Utilization Ratio is 0.18 (2023), against an average of 0.22.
• The sharpest annual moves came in 2024 and 2026: Asset Utilization Ratio jumped 389.05% in 2024, then slumped 95.27% in 2026.
• Entrada Therapeutics' Asset Utilization Ratio stood at 0.27 in 2023, then soared by 44.23% to 0.39 in 2024, then plunged by 83.5% to 0.06 in 2025, then plunged by 74.98% to 0.02 in 2026.
• Business Quant data shows TRDA's Asset Utilization Ratio at 0.02 in Q1 2026, 0.06 in Q4 2025, and 0.14 in Q3 2025.